Age-related cataract is associated with type 2 diabetes and statin use

Optometry and Vision Science

Volumn 89, Issue 8, 2012, Pages 1165-1171

  MacHan, Carolyn M ^a   Hrynchak, Patricia K ^a   Irving, Elizabeth L ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

age related cataract; epidemiology; prevalence; statins; type 2 diabetes

Indexed keywords

AGE-RELATED; CORTICAL CATARACT; CRYSTALLINE LENS; HIGH BLOOD PRESSURES; HMG-COA REDUCTASE INHIBITOR; LOGISTIC REGRESSION ANALYSIS; MULTI VARIABLES; NUCLEAR SCLEROSIS; POSTERIOR SUBCAPSULAR CATARACT; PREVALENCE; RISK FACTORS; STATINS; TYPE-2 DIABETES;

EPIDEMIOLOGY; REGRESSION ANALYSIS;

BLOOD PRESSURE;

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADOLESCENT; ADULT; AGE; AGE DISTRIBUTION; AGED; ARTICLE; CANADA; CATARACT; CHILD; COMPARATIVE STUDY; FEMALE; HUMAN; INFANT; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCHOOL CHILD; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; CATARACT; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFANT; MALE; MIDDLE AGED; ONTARIO; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84864696262     PISSN: 10405488     EISSN: None     Source Type: Journal    
DOI: 10.1097/OPX.0b013e3182644cd1     Document Type: Review

References (37)

1. Delcourt C, Cristol JP, Tessier F, Leger CL, Michel F, Papoz L. Risk factors for cortical, nuclear, and posterior subcapsular cataracts: The POLA study. Pathologies Oculaires Liees a l'Age. Am J Epidemiol 2000;151:497-504.
2. Leske MC, Chylack LT, Jr., Wu SY. The lens opacities case-control study. Risk factors for cataract. Arch Ophthalmol 1991;109:244-51.
3. Mukesh BN, Le A, Dimitrov PN, Ahmed S, Taylor HR, McCarty CA. Development of cataract and associated risk factors: The Visual Impairment Project. Arch Ophthalmol 2006;124:79-85.
4. Tan JS, Wang JJ, Mitchell P. Influence of diabetes and cardiovascular disease on the long-term incidence of cataract: The Blue Mountains Eye Study. Ophthalmic Epidemiol 2008;15:317-27.
5. Hennis A, Wu SY, Nemesure B, Leske MC. Risk factors for incident cortical and posterior subcapsular lens opacities in the Barbados eye studies. Arch Ophthalmol 2004;122:525-30.
6. Klein BE, Klein R, Lee KE. Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of agerelated cataract and progression of lens opacities: The Beaver Dam Eye Study. Am J Ophthalmol 1998;126:782-90.
7. Stenson S. Healthy sight counseling: Diabetes and the eye. Clin Refract Optom 2009;20:248-58.
8. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
9. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008;26:77-82.
10. Hermans MP, Ahn SA, Rousseau MF. Statin therapy and cataract in type 2 diabetes. Diabetes Metab 2010;37:139-43.
11. Behrens-Baumann W, Thiery J, Fieseler HG, Seidel D. Pravastatin- ocular side effects after a two year follow-up? Lens Eye Toxic Res 1990;7:311-8.
12. Schmitt C, Schmidt J, Hockwin O. Ocular drug-safety study with the HMG-CoA reductase inhibitor pravastatin. Lens Eye Toxic Res 1990;7:631-42.
13. Harris ML, Bron AJ, Brown NA, Keech AC, Wallendszus KR, Armitage JM, MacMahon S, Snibson G, Collins R. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford cholesterol study group. Br J Ophthalmol 1995;79:996-1002.
14. Lundh BL, Nilsson SE. Lens changes in matched normals and hyperlipidemic patients treated with simvastatin for 2 years. Acta Ophthalmol (Copenh) 1990;68:658-60.
15. Hartman HA, Myers LA, Evans M, Robison RL, Engstrom RG, Tse FL. The safety evaluation of fluvastatin, an HMG-CoA reductase inhibitor, in beagle dogs and rhesus monkeys. Fundam Appl Toxicol 1996;29:48-62.
16. Zakrzewski P, Milewska J, Czerny K. The eye lens evaluation of the atorvastatin-treated white rat. Ann Univ Mariae Curie Sklodowska Med 2002;57:165-71.
17. Gerson RJ, MacDonald JS, Alberts AW, Chen J, Yudkovitz JB, Greenspan MD, Rubin LF, Bokelman DL. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res 1990;50:65-78.
18. Chodick G, Heymann AD, Flash S, Kokia E, Shalev V. Persistence with statins and incident cataract: A population-based historical cohort study. Ann Epidemiol 2010;20:136-42.
19. Tan JS, Mitchell P, Rochtchina E, Wang JJ. Statin use and the longterm risk of incident cataract: The Blue Mountains Eye Study. Am J Ophthalmol 2007;143:687-9.
20. Klein BE, Klein R, Lee KE, Grady LM. Statin use and incident nuclear cataract. JAMA 2006;295:2752-8.
21. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: Population based cohort study using the QResearch database. BMJ 2010;340:c2197.
22. Machan CM, Hrynchak PK, Irving EL. Waterloo Eye Study: Data abstraction and population representation. Optom Vis Sci 2011;88: 613-20.
23. Machan CM, Hrynchak PK, Irving EL. Modeling the prevalence of age-related cataract: Waterloo Eye Study. Optom Vis Sci 2012; 89: 130-6.
24. Chylack LT, Jr., Leske MC, McCarthy D, Khu P, Kashiwagi T, Sperduto R. Lens opacities classification system II (LOCS II). Arch Ophthalmol 1989;107:991-7.
25. Institute for Clinical Evaluative Sciences (ICES). Diabetes in Ontario:AnICESPractice Atlas: June 2003. Available at: Http://www. ices.on.ca/webpage.cfm?site-id-1&org-id-31&morg-id-0&gsec-id- 0&item-id-1312. Accessed June 11, 2012.
26. Hodge WG, Whitcher JP, Satariano W. Risk factors for age-related cataracts. Epidemiol Rev 1995;17:336-46.
27. Sabanayagam C, Wang JJ, Mitchell P, Tan AG, Tai ES, Aung T, Saw SM, Wong TY. Metabolic syndrome components and age-related cataract: The Singapore Malay Eye Study. Invest Ophthalmol Vis Sci 2011;52:2397-404.
28. Cenedella RJ. Cholesterol and cataracts. Surv Ophthalmol 1996;40: 320-37.
29. Mori M, Li G, Abe I, Nakayama J, Guo Z, Sawashita J, Ugawa T, Nishizono S, Serikawa T, Higuchi K, Shumiya S. Lanosterol synthase mutations cause cholesterol deficiency-associated cataracts in the Shumiya cataract rat. J Clin Invest 2006;116:395-404.
30. McCarty CA, Nanjan MB, Taylor HR. Attributable risk estimates for cataract to prioritize medical and public health action. Invest Ophthalmol Vis Sci 2000;41:3720-5.
31. Ederer F, Hiller R, Taylor HR. Senile lens changes and diabetes in two population studies. Am J Ophthalmol 1981;91:381-95.
32. Neutel CI, Morrison H, Campbell NR, de Groh M. Statin use in Canadians: Trends, determinants and persistence. Can J Public Health 2007;98:412-6.
33. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51.
34. Javitt JC, Wang F, West SK. Blindness due to cataract: Epidemiology and prevention. Annu Rev Public Health 1996;17:159-77.
35. American Academy of Ophthalmology. Cataract in the Adult Eye, Preferred Practice Patterns: 2008. Available at: Http://one.aao.org/ CE/ PracticeGuidelines/PPP.aspx. Accessed October 8, 2008.
36. American Optometric Association. Optometric Clinical Practice Guideline: Care of the Adult Patient with Cataract. Available at http://www.aoa.org/ documents/CPG-8.pdf. Accessed June 11, 2012.
37. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, Rahilly-Tierny C, Thomas F, Berger JS, Ockene JK, Curb JD, Ma Y. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172:144-52.